Small antibodies provide wide protection against Coras Sars

Scientists have discovered a unique category of small antibodies that strongly protect against a wide spectrum of Sars Coras, including SARS-COV-1 and numerous and recent SARS-COV-2 variants. The unique antibodies aim at a basic highly maintained position on the base of the virus pins protein, effectively tightening the closed and preventing the virus from infecting cells. The findings published in the Nature communicationsThey offer a very promising route for the development of wide range of antiviral treatments that could remain effective against future viral variants.

The Sars-COV-2, the virus behind Covid-19, is still a possible threat as it evolves into newer variations that are resistant to today’s approved antibody treatments. Resistance occurs largely because antibodies usually target areas of virus, such as the spike protein receptor area, which is also often mutated, allowing to escape antibodies.

To deal with this, a research team led by Professor Xavier Saelens and Dr. Bert Schepens at VIB-SUNTER CENTER FOR MEDICAL BIOTECHNOLOGY explored a different strategy by focusing on one of the most stable spike protein subunits. The so -called S2 subunit is critical for the virus’s ability to merge with host cells, a process necessary for infection and is more preserved in different quarries.

A molecular clamp in the virus

The team turned to LLAMAS (more specifically a blade called Winter). The almonds create the so -called single -field antibodiesAlso known as VHHS or nannomas, which are much smaller than antibodies produced by most animals, including humans. The researchers identified various Llama antibodies that strongly neutralize a wide panel of sars.

What makes these antibodies particularly promising is their only way of acting: they act as a molecular clamp. They blend in inadequately exposed, extremely preserved area (a coil of 3 Helicic Alpha) at the base of the virus pins protein. In this way, they lock the pins protein in its original shape, naturally preventing the launch in the form the virus needs to infect the cells.

Antibodies showed strong protection against infection in laboratory animals, even in low doses. And when the researchers tried to force the virus to develop resistance, the virus struggled, producing only rare escape variations that were much less infectious. This shows a strong, difficult treatment option.

This area is so important to the virus that it cannot be easily mutated without weakening the virus itself. This gives us a rare advantage: a goal that is both essential and stable in all variants. ”

Professor Xavier Saelens, senior author of the study

Best treatments

This discovery marks a significant progress in the search for durable and widely effective antiviral therapies, offering hope for treatments that can be in line with the progression of the virus.

“The combination of high power, widespread activity against numerous viral variants and a high barrier to resistance is incredibly promising,” Saelens adds. “This work provides a strong basis for the development of next generation antibodies that could be vital to the fight against not only today’s but also future threats to the Koran.”